ABSTRACT
the World Health Organisation (WHO) adopted a strategy to Eliminate Yellow fever Epidemics (EYE) by 2026 . 66
This strategy aims to prevent sporadic cases sparking urban outbreaks, thus minimizing the risk of international 67 spread [5] . The EYE strategy largely relies on, but is not limited to, scale-up of vaccination. 68
Vaccination activities considered in the EYE strategy consist of routine immunization of infants, preventive 69 mass vaccination campaigns (PMVCs) that target all or most age groups, preventive catch-up campaigns 70 targeting specific cohorts or unvaccinated sub-populations, and reactive campaigns in outbreak situations. Local 71 assessment of YF transmission intensity is key for the prioritization of each of these vaccination activities; 72 particularly since the supply of vaccine is limited as seen during the 2016 Angola outbreak [6, 7] . Vaccine 73 demand forecasts are critical to shape vaccine production and ensure optimal vaccine allocation. 74
Previous mathematical models have assessed geographical heterogeneity in YF risk [8] [9] [10] . However, modelling 75 is challenging because of the co-existence of different transmission cycles [11] . In the sylvatic cycle, tree-76 dwelling mosquitoes transmit the virus within the wildlife reservoir (non-human primates) and spill-over 77 infection may occur for humans living or working in jungle habitats. In the urban cycle, the domestic mosquito 78
Aedes aegyptii transmits the virus between humans. Population ('herd') immunity (whether via natural infection 79 or vaccination) will be expected to modify transmission intensity within the urban cycle, but not in the sylvatic 80 cycle where transmission intensity is driven by non-human primates and their interactions with human 81 populations. Recently, two models quantifying the incidence of the disease in Africa or worldwide have been 82 used to derive estimates for vaccination impact [9, 10] . Both assumed a constant force of infection over time, 83 thus disregarding possible herd effects that may arise in urban context due to changing population-level 84
immunity. 85
Accelerated urbanization and increasing human population mobility might increase the contribution of the urban 86 transmission cycle to the global YF burden. Urban cases have the potential to trigger explosive outbreaks that 87 can place a substantial burden on health systems, as well as causing significant social and economic impacts. 88 spread more likely. Thus, accounting for specific features of urban transmission will be useful to assess the risk 91 of urban outbreaks and refine the estimates of vaccine impact. 92
In this paper, we have extended of a previously developed model [9] to account for specific features of inter-93 human transmission. We then compare this model to the previous version (which focussed on sylvatic 94 transmission) and update previous estimates of YF burden and vaccine impact, accounting for indirect effects. 95
Lastly, based on local estimates of the potential for inter-human urban transmission, we propose different 96 scenarios of PMVCs that could be considered for the EYE strategy, evaluating vaccine demand and impact in 97 terms of infections and mortality averted. 98 99 100
Material and methods

101
The Yellow Fever burden model [9] was developed to estimate YF disease burden and vaccine impact across 34 102 African countries at high or moderate risk for YF [5] . The original model was developed assuming that the 103 locally-fitted force of infection (the annual probability of infection for a susceptible individual), 2013 at the first sub-national administrative level (hereafter called province), using various environmental and 112 demographic covariates. We defined a reported YF event as either outbreak reports published by WHO or 113 laboratory-confirmed cases reported in a YF surveillance database managed by WHO-AFRO, to which 21 114 countries contribute. 115
The GLM provides estimates of the probability of any YF report across the endemic zone over the 30-year 116 period considered. In a second step, we describe this probability of a report as dependent on the number oftransmission intensity, obtained by fitting 12 serological surveys performed in 11 African countries. 119
The two model versions differ in the way they fit serological data. In the static version of the model (thereafter 120 termed "FOI model",) a constant, age-independent force of infection (FOI) λ is fitted to each serological survey. 121
Alternatively, in the dynamical version of the model (thereafter termed "R 0 model"), a basic reproduction 122 number R 0 is fitted, based on the classical SIR model framework under the assumption of endemic equilibrium 123 transmission [12] . 124
The GLM quantifies geographic variation of the relative risk of YF transmission across the continent while each 125 serological survey yields an estimate of the absolute transmission intensity in its specific location. for a specific year, vaccination activities happen to increase the immunized proportion of the population above 135 the herd immunity threshold, 1 -1/ R 0 (also known as the Critical Vaccination Coverage, CVC), then no new 136 infection will be expected in that year. In that case, the unvaccinated proportion of the population is indirectly 137 but fully protected by herd immunity. Note, that when there is no history vaccination, both models agree. 138
139
Model fitting and burden estimates 140
The model is fitted in a Bayesian framework using Markov chain Monte Carlo simulations. We assumed a prior 141 distribution for vaccine efficacy centred at 97.5% (95% confidence intervals: 82.9% to 99.7%) [14] , with no 142 waning of immunity [15] . The models were fitted based on the best yearly estimates of vaccination coverage 143
[13]. Posterior samples of parameters were used to compute medians and 95% credibility intervals (CI) of model 
Results
180
Based on the YF surveillance database and publicly-available reports, YF had been reported at least once over 181 the 1984-2013 period in 160 of 479 provinces ( Figure 1A ). The GLM captured the presence/absence of YF well 182 with an area under the ROC curve >0.9 for both model variants (Table 1 and S1 Figure) . 2017 total number of DALYs lost 5,400,000 (1,900,000 -13,600,000) 1,700,000 (240,000 -7,000,000)
Lifetime vaccine impact estimates* of 2005-2017 PMVCs
Deaths prevented 3,300,000 (1,200,000 -7,700,000) 6,100,000 (2,400,000 - 
228 229
Estimates of the YF-specific burden are presented in Table 1 . We estimate 107,000 deaths (37,000-272,000) 230 occurred in 2017 according to the FOI model and 30,000 (4,000-123,000) according to the R 0 model. As 231 expected from its non-linear response to vaccination, the R 0 model was more sensitive to variations in 232 vaccination coverage and predicted a higher burden than the FOI model before the implementation of mass 233 vaccination campaigns, but a lower burden thereafter (S5 Figure) . Of note, with no or low-level of vaccination 234 coverage as in Eastern Africa, both model versions exhibited similar temporal trends (S6 Figure) . Province-235 based burden estimates are presented in Figure 4 . While the assumption of endemic equilibrium forced the FOI 236 model to predict a non-zero force of infection, large parts of the endemic zone exhibited very low incidence 237 rates (notably in Rwanda and Burundi). In contrast, the R 0 model predicted a zero incidence in all provinces 238 where the vaccination coverage exceeded the local CVC. Large regions of Eastern Africa, that did not benefit 239 from any vaccination activities, still exhibited small incidence rates. were estimated to have already prevented 700,000 (200,000-1,600,000) deaths as of 2017 and will prevent a 249 further 2,600,000 (1,000,000-6,100,000) deaths over the lifetime of the vaccinees. According to the R 0 model, 250 2,600,000 (1,000,000-6,000,000) deaths have been prevented as of 2017 and 3,400,000 (1,300,000-7,400,000) 251 future deaths will be prevented by those campaigns. 252 would prevent 9,900,000 (7,000,000-13,400,000) infections and 480,000 (180,000-1,140,000) deaths over the 257 lifetime of the vaccinees, corresponding to 1.7 (0.7-4.1) deaths averted per 1,000 vaccine doses (Table 2) . 258
Broader strategies would result in larger number of deaths prevented at the cost of lower impact per doses. 
Discussion
277
By combining a regression model fitted to the reported local presence of YF with serological data collected in 278 11 countries, this modelling study presents updated estimates of YF burden across 34 African countries in terms 279 of number of infections, severe cases, deaths, and DALYs. We also estimated that PMVCs conducted since 280
2006 will prevent a total of 3 to 6 million deaths over the lifetime of vaccinees, depending on whether we 281 assume transmission is dominated by the sylvatic or the urban cycles, respectively. As both transmission cycles 282 do contribute to the disease burden, the real impact of vaccination likely lies between these two extreme cases. substantial, covering more than one order of magnitude for some estimates. As our model integrates all existing 294 data on YF that are currently available for Africa, such uncertainty reflects the current lack of accurate 295 knowledge regarding YF incidence and epidemiology. 296
The two model variants we developed exhibited substantial differences in resulting estimates of YF burden and coverage is not directly accounted for in our model, but may be propagated in the efficacy parameter of the 335 model. Indeed, the posterior distribution of vaccine efficacy is much wider than the range documented in a 336 recent meta-analysis [14], especially for the R 0 variant which is expected to be more sensitive to vaccine 337 coverage. Lastly, in the absence of more detailed data, vaccination activities were often assumed to be 338 implemented homogeneously across space in particular for RI, glossing over existing heterogeneities in 339 coverage. Recent efforts to document such heterogeneity, such as the YF EPI warning system developed by theheterogeneity in the disease using a statistical rather than a mechanistic approach. Our model does not explicitly 343 represent the spatial distribution of vectors nor disease reservoirs unlike Shearer et al's model [10] . However, 344 the set of spatial predictors we used has been demonstrated to have good predictive power for both presence and 345 seasonality of YF [28] . To our knowledge, our model is the only one calibrated against serological data that 346 captures the whole spectrum of disease severity. Other YF burden estimates stem from models calibrated on 347 reported cases [10, 29] , that may lead to underestimation due to under-reporting and misdiagnosis. For instance, 348 the Global Burden of Disease estimates for 2016 around 5,000 YF-deaths in Africa, which is near to the lower 349 bound of our R 0 model estimates. Lastly, the development of the R 0 variant of our model constitutes a novel 350 approach to account for herd effects in the impact of YF vaccination. Our results highlight that heterogeneity in 351 transmission intensity imply different vaccination threshold to be reached in order to prevent YF outbreaks. This 352 can be used to locally adapt the empirical threshold of 80% vaccination coverage that is often considered 353 sufficient for YF outbreak prevention [11] . 354
Using local estimates of the potential for urban outbreaks for PMVCs prioritization, we explored several 355 vaccination scenarios ranking from a parsimonious strategy focussed on high-risk areas to an ambitious large-356 scale approach targeting the vast majority of provinces within the at-risk region. Recent years have shown that 357 efforts to control YF outbreaks were highly constrained by the stock of vaccine doses available for emergency 358 situation [30] . Optimal vaccine allocation is also crucial in the context of preventive vaccination activities. By 359 contrasting the impact of several scenarios with the corresponding vaccine demand, and also by suggesting a 360 sequence of implementation within each scenario, this study helps in the search for optimal vaccine allocation. 361
We do acknowledge however that a realistic strategy will need to take into account further factors such as 362 operational or political concerns. 363
Patterns of YF transmission seem to have changed in the recent years toward shorter transition from the sylvatic 364 cycle to urban inter-human transmission [5] . Renewed disease control strategies thus need to account for this 365 change in implementation of control measures. This study addressed this challenge by developing a vaccine 366 impact modelling framework accounting for urban YF transmission. This work has contributed to a risk 367 assessment conducted as part of the EYE strategy in order to prioritize countries for PMVCs [31] . 
